Accuracy and Prognostic Significance of Oncologists' Estimates and Scenarios for Survival Time in A Randomised Phase II Trial of Regorafenib in Advanced Gastric Cancer

dc.contributor.authorVasista, A
dc.contributor.authorMartin, Andrew
dc.contributor.authorPavlakis, N.
dc.contributor.authorSjoquist, Katrin
dc.contributor.authorSnow, Stephanie
dc.contributor.authorJonker, Derek J
dc.contributor.authorChua, YuJo
dc.contributor.authorEpstein, Richard
dc.contributor.authorBonaventura, Antonino
dc.contributor.authorKhasraw, M
dc.contributor.authorVarma, Suresh
dc.coverage.spatialSydney, Australia
dc.date.accessioned2022-06-17T00:14:35Z
dc.date.created13-15 November
dc.date.issued2017
dc.date.updated2021-02-14T07:22:21Z
dc.description.abstractBackground: We have proposed that best, worst and typical scenarios for survival, based on simple multiples of an individual's expected survival time (EST) estimated by their oncologist, are a useful way of formulating and explaining prognosis in advanced cancer. We aimed to determine the accuracy and prognostic significance of such estimates in a multicentre, randomised trial. Methods: Sixty‐six oncologists estimated the EST at baseline for each of 152 participants in the INTEGRATE trial. We expected oncologists’ estimates of EST to be well calibrated (∼50% of patients living longer than their EST) and imprecise (<33% living within 0.67–1.33 times their EST), but to provide accurate scenarios for survival time (∼10% dying within a quarter of their EST, ∼10% living longer than three times their EST and ∼50% living for half to double their EST). We hypothesised that oncologists’ estimates of EST would be independently predictive of overall survival in a Cox model including conventional prognostic factors. Results: Oncologists’ estimates of EST were well calibrated (45% shorter than observed), imprecise (29% lived within 0.67–1.33 times observed), and moderately discriminative (Harrell C‐statistic 0.62, P = 0.001). Scenarios derived from oncologists’ estimates were remarkably accurate: 9% of patients died within a quarter of their EST, 12% lived longer than three times their EST and 57% lived within half to double their EST. Oncologists estimates of EST were independently significant predictors of overall survival (HR = 0.89; 95% CI, 0.83–0.95; P = 0.001) in a Cox model including conventional prognostic factors. Conclusions: Oncologists’ estimates of survival time were well calibrated, moderately discriminative and independently significant predictors of overall survival. Best, worst and typical scenarios for survival based on simple multiples of the EST were remarkably accurate and would provide a useful method for estimating and explaining prognosis in this setting.en_AU
dc.format.mimetypeapplication/pdfen_AU
dc.identifier.issn1743-7555en_AU
dc.identifier.urihttp://hdl.handle.net/1885/267349
dc.language.isoen_AUen_AU
dc.publisherWileyen_AU
dc.relation.ispartofseriesCOSA's 44th Annual Scientific Meeting, Immunotherapy: Molecules and Mountainsen_AU
dc.sourceAsia-Pacific Journal of Clinical Oncologyen_AU
dc.titleAccuracy and Prognostic Significance of Oncologists' Estimates and Scenarios for Survival Time in A Randomised Phase II Trial of Regorafenib in Advanced Gastric Canceren_AU
dc.typeConference posteren_AU
local.bibliographicCitation.issueS4en_AU
local.bibliographicCitation.lastpage138en_AU
local.bibliographicCitation.startpage138en_AU
local.contributor.affiliationVasista, A, University of Sydneyen_AU
local.contributor.affiliationMartin, Andrew, University of Sydneyen_AU
local.contributor.affiliationPavlakis, N., University of Sydneyen_AU
local.contributor.affiliationSjoquist, Katrin, NHMRC Clinical Trials Centreen_AU
local.contributor.affiliationSnow, Stephanie, Queen Elizabeth II Health Science Centreen_AU
local.contributor.affiliationJonker, Derek J, University of Ottawaen_AU
local.contributor.affiliationChua, YuJo, College of Health and Medicine, ANUen_AU
local.contributor.affiliationEpstein, Richard, St. Vincent's Hospitalen_AU
local.contributor.affiliationBonaventura, Antonino, ANZGOGen_AU
local.contributor.affiliationKhasraw, M, University of Sydneyen_AU
local.contributor.affiliationVarma, Suresh, Townsville Hospitalen_AU
local.contributor.authoremailrepository.admin@anu.edu.auen_AU
local.contributor.authoruidChua, YuJo, u5101833en_AU
local.description.embargo2099-12-31
local.description.notesImported from ARIESen_AU
local.description.refereedYes
local.identifier.absfor110307 - Gastroenterology and Hepatologyen_AU
local.identifier.absfor111204 - Cancer Therapy (excl. Chemotherapy and Radiation Therapy)en_AU
local.identifier.absseo920105 - Digestive System Disordersen_AU
local.identifier.absseo920102 - Cancer and Related Disordersen_AU
local.identifier.ariespublicationu5369653xPUB245en_AU
local.identifier.citationvolume13en_AU
local.identifier.doi10.1111/ajco.12799en_AU
local.identifier.uidSubmittedByu5369653en_AU
local.publisher.urlhttps://www.wiley.com/en-gben_AU
local.type.statusPublished Versionen_AU

Downloads

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
01_Vasista_Accuracy_and_Prognostic_2017.pdf
Size:
1.93 MB
Format:
Adobe Portable Document Format